A Commercialization Model Developed for Oncology and Hematology

Traditionally, manufacturers preparing to launch had three commercialization options: sell, out-license or launch on their own. However, these options may not be ideal for new oncology therapies. Similar to the way contract research organizations disrupted the market in the ’90s before becoming an industry staple, EVERSANA’s fourth commercialization option is the next phase of evolution for pharma.

EVERSANA ONCOLOGY Commercialization is the optimal solution for oncology and hematology drug manufacturers. Through our award-winning commercialization model and innovative cancer drug launch strategy, our partners optimize their investments, minimize risk and increase speed to market.

Key Benefits of the EVERSANA ONCOLOGY Commercialization Model

• Delivers more value than traditional licensing or launching on your own with a true partnership structure.
• Activates a complete, ready-to-deploy, high-performance commercialization and distribution engine.
• Accelerates your product from early development to marketing, effectively impacting patient outcomes and beyond.
• Provides access to a deep bench of industry experts across all commercial services.
• Offers manufacturers the flexibility to customize their strategies and build functional service areas.
• Meets you where you are on the commercial continuum.
• Maximizes and compliments existing internal resources allowing access to new drug candidates and technologies in oncology.
• Supports the entire product lifecycle by reviving established brands and reigniting revenue.

True Financial Benefit

A recent study examined 10 real-world pharma launches and compared them to companies that embraced this new, innovative, scalable commercialization model. The study concluded that those who launched in the traditional model overspent by 23%, without any upside on launch success. Download the white paper to see an in-depth analysis of all launches and costs.